A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E, Oliveira M, Turner N, García-Corbacho J, Hernando C, Ciruelos EM, Kabos P, Borrego MR, Armstrong A, Patel MR, Vaklavas C, Twelves C, Boni V, Incorvati J, Brier T, Gibbons L, Klinowska T, Lindemann JPO, Morrow CJ, Sykes A, Baird R.
Hamilton E, et al. Among authors: patel mr.
Ann Oncol. 2024 May 8:S0923-7534(24)00138-8. doi: 10.1016/j.annonc.2024.04.012. Online ahead of print.
Ann Oncol. 2024.
PMID: 38729567
Free article.